BioSymetrics

Next up in our Pheno-Type highlight series is?Denise Johnston, Manager of Operations & People Experience at BioSymetrics. In this feature, she shares her unique career journey, and her insights on bridging science and operations and the transformative effects of AI on drug discovery and healthcare. Click through to read more! https://lnkd.in/gBydAGDG #ai #drugdiscovery

Next up in our Pheno-Type highlight series is Steven Bishop, Solutions Architect. In this feature, he talks about his journey to BioSymetrics and his perspectives on data and collaboration in biotechnology. Click through to read more! https://lnkd.in/gdZq2fJx #ai #drugdiscovery

Throwback time! ?? Here’s a blast from the past from our Halloween costume party a couple of years ago, where creativity, costumes, and laughs took centre stage! Wishing you all a frightfully fun Halloween from our team to yours! ?? #Halloween #TeamFun #Throwback

Next up in our Pheno-Type highlight series is Michele Arena, PMP, Director of Project Management. In this feature, she talks about her transition from clinical practice to project management, ultimately landing at BioSymetrics. Click through to read more! https://lnkd.in/gPMtWGy5 #ai #drugdiscovery

A joy of being based in Canada and the United States is that we get to celebrate two Thanksgivings. (Whether this translates to twice the turkey is anyone’s guess!) Happy Thanksgiving Day to our Canadian team members! #ThanksgivingDay

Our next entry in our Pheno-Type series, highlighting our team members, features Kevin Ha, Head of Data Science, Genomics. In this feature, he talks about his journey from bioinformatics to BioSymetrics. Click through to read more! https://lnkd.in/eHSR-zik #ai #drugdiscovery

We are excited to announce our strategic partnership with Moleculera Biosciences to combine our AI-driven Elion platform with Moleculera’s expansive biorepository and bioinformatics dataset. Together, we aim to develop advanced predictive treatment algorithms that can revolutionize how clinicians identify and treat immune-mediated neurologic and psychiatric disorders – eliminating trial and error and improving patient outcomes. Read our press release here: https://lnkd.in/gRyat5Xf #AI #Bioinformatics #Neurology #PrecisionMedicine

We are resuming our Pheno-Type series! Victoria Catterson, Vice President of Data Science Research, features in our first team member highlight of this series. In this feature, she talks about her leap from diagnostics in power equipment to BioSymetrics. Click through to read more! https://lnkd.in/dAuQPyk4 #ai #drugdiscovery

We collaborated with a group from Parent Project Muscular Dystrophy, from Leiden University Medical Center and University of Florida, to identify biomarkers of disease progression in Duchenne muscular dystrophy (#DMD). A preprint of our work is now available on medRxiv. Special thanks to Shahrzad Hosseini and Simon Eng for leading this work for BioSymetrics! See the preprint here: https://lnkd.in/d7jhJRWn

Join us as we celebrate the 5th anniversary of BioSymetrics' Canadian subsidiary this week! We started our Canadian operations in 2019 from a little office space in Toronto. Since then our Canadian team has expanded beyond Toronto, to Charlottetown on the east coast and Vancouver on the west coast! Our Canadian Machine Learning team has been at the forefront of various BioSymetrics technologies, including our proprietary Phenograph, Computer Vision, and MOA Miner platforms. Special thanks to Gabriel Musso, Victoria Catterson , and Kevin Ha for co-founding our Canadian team and paving the way for our future success!